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The lack of adipose triglyceride lipase (ATGL), a patatin-like phospholipase domain-containing enzyme that
hydrolyzes fatty acids from triacylglycerol (TAG) stored in multiple tissues, causes the autosomal recessive
disorder neutral lipid storage disease with myopathy (NLSD-M). In two families of Lebanese and Italian origin
presenting with NLSD-M, we identified two new missense mutations in highly conserved regions of ATGL
(p.Arg221Pro and p.Asn172Lys) and a novel nonsense mutation (p.Trp8X). The Lebanese patients harbor
homozygous p.Arg221Pro, whereas the Italian patients are heterozygotes for p.Asn172Lys and the p.Trp8X
mutation. The p.Trp8X mutation results in a complete absence of ATGL protein, while the p.Arg221Pro and
p.Asn172Lys mutations result in proteins with minimal lipolytic activity. Although these mutations did not
affect putative catalytic residues or the lipid droplet (LD)-binding domain of ATGL, cytosolic LDs accumu-
lated in cultured skin fibroblasts from the patients. The missense mutations might destabilize a random
coil (p.Asn172Lys) or a helix (p.Arg221Pro) structure within or proximal to the patatin domain of the
lipase, thereby interfering with the enzyme activity, while leaving intact the residues required to localize
the protein to LDs. Overexpressing wild-type ATGL in one patient’s fibroblasts corrected the metabolic
defect and effectively reduced the number and area of cellular LDs. Despite the poor lipase activity in
vitro, the Lebanese siblings have a mild myopathy and not clinically evident myocardial dysfunction. The
patients of Italian origin show a late-onset and slowly progressive skeletal myopathy. These findings suggest
that a small amount of correctly localized lipase activity preserves cardiac function in NLSD-M.
INTRODUCTION
Human adipose triglyceride lipase (ATGL), a member of
the patatin-like phospholipase domain-containing proteins
(PNPLA) (1) that hydrolyze fatty acids from triacylglycerol
(TAG) stored in multiple tissues, is a 504 amino acid
protein containing the GXSXG serine hydrolase motif that is
part of the catalytic dyad essential for lipase activity (2).
ATGL also contains a C-terminus domain whose hydrophobic
portion is required for binding to lipid droplets (LDs) (3). The
expression of ATGL (also called PNPLA2, desnutrin, and
calcium-independent phospholipase A2z) (1,4,5) is highest in
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brown and white adipose tissue, but is also present in heart,
skeletal muscle, and most other tissues (1,5–7).
The absence of ATGL results in neutral lipid storage disease
with myopathy (NLSD-M; MIM 610717) (8), an autosomal re-
cessive disorder characterized by vacuolated granulocytes
(Jordan’s anomaly), cardiac and skeletal muscle myopathy,
and LD storage in most tissues (9). Most of the reported
ATGL mutations that cause NLSD-M result in truncated
proteins with an unaltered catalytic site, but with defects in
the C-terminus region which binds to LDs (8,10–12). These
mutations indicate that preserving the lipase activity does
not prevent NLSD-M if the enzyme cannot bind to LDs (3,12).
On the other hand, mutations located in the patatin/catalytic
domain which severely impair the lipolytic capacity of the
ATGL enzyme cause the complete expression of NLSD-M
phenotype (8,13–16). A total loss of function is associated
with a severe clinical phenotype in both humans and a
rodent model (17). However, the clinical and biochemical
impact of ATGL mutations that do not alter ATGL binding
to LDs and also retain some lipase activity is less well charac-
terized.
We now describe the clinical findings in four NLSD-M
patients and report two novel missense mutations and a
novel nonsense mutation in the ATGL gene. The nonsense mu-
tation results in the lack of protein production, whereas the
missense mutations severely diminish lipase activity, although




Patient 1A, reported in 1994 (18), is now 28 years old. Al-
though he works as a caterer, he becomes exhausted after
climbing three flights of stairs. He can run about 30–50 m.
At 26 and 27 years of age, he reported chest discomfort. An
echocardiogram showed hyperechogenic areas in the heart
muscle. The electrocardiogram showed no arrhythmia.
Plasma creatine kinase values were 4200 and 3800 IU/l
without an increase of creatine kinase (CK)-MB, and troponin
was negative. A stress test showed a maximum power of 125
watts (heart rate of 133 beats/min) with no signs of cardiac is-
chemia. The patient has been otherwise well except for epi-
sodes of pancreatitis in 2005 and in 2011 that required
treatment in an intensive care unit. His leucocytes showed
Jordan’s anomaly (Fig. 1B).
Patient 1B, the unemployed 33-year-old sister of patient 1A,
is physically limited. She can climb a single flight of stairs
with difficulty and can walk slowly, but only for 30 min
because she experiences leg cramps and shortness of breath.
She also complains of painful cramps in her legs which
occur without exercise and which require her to use a car
with hand controls. She has muscle spasms of her hands and
fingers, sometimes lasting for hours. Plasma CK values were
897 IU/l. Her gall bladder was removed at age 26 because of
multiple gall stones. She has chronic diarrhea of unknown
cause. She has not had pancreatitis or diabetes mellitus and
has not been evaluated by a cardiologist. Her three
pregnancies were complicated by prolonged labor and
looping of the umbilical cords. Her leucocytes showed
Jordan’s anomaly.
Family 2 (Italian)
Patient 2A, an unemployed 65-year-old woman, has hyperten-
sion and hypothyroidism. She first noted leg myalgia and
cramps at age 25. At 40 years of age, her electromyography
(EMG) showed myotonic discharges (Fig. 1F). In 1995, the
histological diagnosis was made: a muscle biopsy showed
excess Oil Red O (ORO) staining (Fig. 1E), and transmission
electron microscopy confirmed a lipid storage myopathy. Her
leucocytes showed Jordan’s anomaly. Serum and muscle car-
nitine levels and carnitine palmitoyltransferase activity were
normal. Her CK was normal until she was 40 years old, but
now ranges between 440 and 730 IU/l. Cardiac ultrasound
and scintigraphy in 2005 showed mild hypertrophic cardiomy-
opathy. She has been subjected to regular clinical cardiologic-
al controls until 2011. Holter electrocardiogram (ECG)
performed in 2011 showed slight tachycardia, signs of left
ventricular pressure overload, no pauses and no significant al-
teration of S-T tract. She currently has severe weakness in her
upper arms with deltoid strength of 1–2/5 and quadriceps 3–
4/5 (Medical Research Council scale). She can rise from a
chair with support, but is unable to abduct her arms and
cannot cut her food or brush her hair. She climbs stairs by
pulling herself up, using the bannister and with the help of
an assistant. One of her two sons has an elevated plasma CK
concentration.
Patient 2B, the 58-year-old brother of patient 2A, is a pho-
tographer who first presented with Jordan’s anomaly. He
enjoyed competitive sports until age 40 when he first experi-
enced painful leg cramps. He has proximal lower limb weak-
ness with quadriceps strength of 4.5/5 and gluteus maximus
strength of 4/5 (Medical Research Council scale), a waddling
gait and exertional dyspnea and fatigue after walking 1 km.
He complains of painful cramps in his legs at rest, which
are partially steroid responsive. Upper arm strength is
normal. An EMG showed myotonic discharges. Cardiac ultra-
sound and scintigraphy in 2005 and 2008 showed left ven-
tricular hypertrophy (1.7 mm), an aneurysm of the
interventricular septum, an ejection fraction of 66% and
mild perfusion defects after exercise. The ECG after effort
was normal. In 2011 a transthoracic echocardiogram showed
a normal ejection fraction, a ventricular septal defect
without shunting and a mild increase in left atrial dimension.
Twenty-four hour Holter monitoring did not record significant
arrhythmias. Routine laboratory tests remain within the
normal range, but plasma CK values range from 380 to 680
IU/L, and recent plasma cholesterol concentrations were 248
and 273 mg/dl.
Mutation in family 1. Analysis of the ATGL gene in fibroblasts
from patient 1A (18) showed a new homozygous mutation,
c.662G.C (p.Arg221Pro) (Fig. 1A). This mutation was not
observed in .100 alleles from control subjects, and it was
submitted to GenBank (accession number HQ651812). The
same mutation was identified in DNA extracted from periph-
eral blood from patient 1B. Because ATGL mRNA and
protein were normally expressed in the patient’s fibroblasts
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(Fig. 1C), we aligned the protein sequences orthologous to
human ATGL aa 211–231 (Hs) to that identified in the
genomes of 10 mammals and observed that the p.Arg221Pro
mutation is located in a highly conserved region of the
ATGL protein (Supplementary Material, Fig. S1). Although
the mutation is not within the patatin domain, we hypothesized
that it might affect the function and/or location of ATGL.
In support of this interpretation, the TAG content of fibro-
blasts from patient 1A was 2-fold higher than that of control
fibroblasts (control: 1.55 nmol TAG/mg protein; patient:
3.1 nmol TAG/mg protein) with no change in the cellular
content of cholesterol, cholesterol esters or phospholipids
(Fig. 2A). However, the combined content of diacylglycerol
and monoacylglycerol was 20% lower (control 0.75 nmol/mg
protein; patient: 0.6 nmol/mg protein). Analysis of the fatty
acid composition of TAG showed that the mutant fibroblasts
contained 1.45- to 2-fold more 16:0 (control: 10.5%; patient:
21.5%; p/c ¼ 2), 16:1 (control: 3%; patient: 5.7%; p/c ¼
1.9), 18:0 (control: 12.7%; patient: 20.2%; p/c ¼ 1.59) and
18:1 (control: 20.4%; patient: 29.5%; p/c ¼ 1.45) than
control cells and significantly lower amounts of 20–24
carbon, n-3 and n-6 fatty acid species (Fig. 2B).
Figure 1. Molecular and histochemical characterization of NLSD-M patients. (A) Electropherogram of the ATGL exon-5 sequence harboring the c.662G.C
mutation in patients 1A/B; (B) microphotograph of LDs from patient 1B on buffy coats stained with May-Grünwald-Giemsa; (C) expression of ATGL in
control and disease fibroblasts (patients 1A/B) at comparable passages as evaluated by RT-PCR and western blotting; (D) electropherograms of ATGL
exon-2 and 5 sequences with the c. 24G.C and the c. 516C.A mutations, patients 2A/B; (E) light microscopy of frozen transverse section of a skeletal
muscle biopsy from patient 2A stained with ORO; (F) electromyographic pattern of patient 2A showing myotonic discharges.
5320 Human Molecular Genetics, 2012, Vol. 21, No. 24
When fibroblasts were incubated for 18 h with 400 mM oleic
acid (OA), the amount of accumulated lipid was equivalent in
the patient and control cells. At 200 mM, although the patient’s
cells accumulated less lipid during the incubation, loss of lipid
was almost completely abrogated during the chase, so that
after 96 h, the patient’s cells contained 9.6-fold more TAG
than the control cells (Fig. 2C; Supplementary Material,
Fig. S2). Adding triacsin C to the cells that had been labeled
with [3H] OA showed that these differences in lipid accumu-
lation had resulted from diminished lipid hydrolysis.
Because triacsin C is an inhibitor of several acyl-CoA synthe-
tases, it blocks the synthesis of acyl-CoA used for
re-esterification and promotes the release of hydrolyzed fatty
acids into the media. When triacsin C was present for 48 h,
normal fibroblasts released 3.2-fold more [3H] OA than did
the patient’s fibroblasts (Fig. 2D). The patient’s fibroblasts
showed a 60% lower TAG lipase specific activity at pH 8,
but not at pH 7.2 or pH 6 (Fig. 2E).
To confirm that the retention of LDs and lower TAG lipase
activity had resulted from the mutant ATGL (Arg221Pro), we
transfected patient A1’s fibroblasts with either EGFP or
ATGL-EGFP (Fig. 3A). Overexpressing the normal ATGL
decreased the number of ORO-stained LDs by 90.6% and
decreased their area by 84% (Fig. 3B).
Mutations in family 2. The Italian patients 2A and 2B were
compound heterozygotes for two novel mutations, c.24G.C
(p.Trp8X) and c.516C.A (p.Asn172Lys) (Fig. 1D). These
mutations were not observed in .100 alleles from control
subjects, and they were submitted to GenBank (accession
numbers: JF279441 and JF279442). Because the p.Trp8X
causes the production of an ATGL peptide of only eight
amino acids, the allele carrying this mutation can be consid-
ered a ‘null allele’. The second variation is a missense muta-
tion, p.Asn172Lys. This mutation is located in the terminal
region of the patatin-like domain. Alignment of the protein
Figure 2. Biochemical phenotype of the patient’s 1A cultured skin fibroblasts. (A) Composition of the lipid fraction of confluent fibroblasts, determined in trip-
licate by TLC. ∗P , 0.05; ∗∗∗P , 0.001. (B) Relative fatty acid composition of TAGs isolated from fibroblasts. The values are the mean of three independent
GLC analyses. ∗∗P , 0.01. (C) OA pulse-chase experiments on patient and control fibroblasts. Fluorescence images (Supplementary Material, Fig. S2) were
analyzed for pixel density per cell. (D) OA pulse-chase experiments on patient and control fibroblasts adding to the culture medium 200 mM OA complexed
to BSA and enriched with [3H]OA (1.2 mCi/well). (E) Acylglycerol hydrolase activity of LDs isolated from control and patient fibroblasts was measured at
three different pH values (6, 7.2 and 8). Detailed methods are reported in the Supplementary Material.
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sequences orthologous to human ATGL, aa 162–182, revealed
that the p.Asn172Lys mutation is located in a highly con-
served region of the patatin domain of the ATGL protein (Sup-
plementary Material, Fig. S1).
Functional study of missense ATGL mutations
To verify the pathogenic effect of ATGL allelic variations
identified in our patients, we constructed different recombin-
ant plasmids, each with EGFP at the N-terminus. The plasmids
contained either human ATGL cDNA (pATGL-EGFP), human
ATGL with the p.Arg221Pro mutation (pATGL(Arg221Pro)-
EGFP) and human ATGL with the p.Asn172Lys mutation
(pATGL(Asn172Lys)-EGFP). For comparison, we constructed
human ATGL with p.Ser47Ala and p.Asp166Gly mutations
(pATGL(Ser47Ala)-EGFP), (pATGL(ASp166Gly)-EGFP). Ser
47 and Asp 66 are invariant residues in the core of the catalytic
domain and essential for ATGL enzyme activity (19). Finally,
we performed mutagenesis for all ATGL missense mutations
previously reported for NLSD-M patients (p.Pro195L,
p.Gly483Arg).
When HeLa cells were transiently transfected with either
pATGL-EGFP or mutated ATGL recombinant plasmids and
then incubated with 400 mM OA bound to bovine serum
albumin (BSA), both wild-type ATGL and all ATGL mutant
proteins were observed on LDs (Fig. 4A). Compared with
the vector control, transfection of pATGL-EGFP reduced the
number and area of the LDs 91% and 96.25%, respectively
(Fig. 4B and C, WT). As expected, the two transfected
mutant ATGL plasmids carrying p.Ser47Ala and
p.Asp166Gly mutations had little effect, suggesting that the
TAG lipase activity associated with these variants was
almost absent (Fig. 4B and C, M0 and M1). Considering
ATGL(Ser47Ala) and ATGL(Asp166Gly) proteins as totally
inactive (virtually no normal activity), transfection of the
mutant proteins ATGL(Asn172Lys) and ATGL(Arg221Pro)
suggested that a residual enzymatic activity might be
present. With ATGL(Asn172Lys), the number of LDs per
cell is 21.63% lower and the area of LD sections is 51.23%
lower. With ATGL(Arg221Pro), the number of LDs per cell
is 8.8% lower and the area of LD sections is 28.78% lower
(Fig. 4B and C, M2 and M4). The pATGL(Gly483Arg)
mutant protein is almost completely active and reduces the
number and the area of LDs 84.93% and 94.63%, respectively
(Fig 4B and C, M5). In contrast, the activity of pATGL(-
Pro195Leu) was severely impaired, similar to that of pAT-
GL(Arg221Pro) (Fig. 4B and C, M3).
DISCUSSION
NLSD results from deficiencies of either ATGL or CGI-58 (9),
a 39 kDa protein that associates with LDs and is both a coac-
tivator of ATGL (20) and a lysophosphatidic acid acyltransfer-
ase (21,22). Patients with deficiencies of either CGI-58 or
ATGL have vacuolated granulocytes and excess TAG
storage in LDs in multiple tissues. Clinically, the primary dif-
ference between the two deficiencies is that a lack of CGI-58
results in ichthyosis, whereas a lack of ATGL causes skeletal
and cardiac myopathy. Atgl null mice accumulate excess TAG
in virtually all tissues, and in contrast to the disorder in
humans, have larger adipose depots than wild-type controls
(17). The heart is severely affected in Atgl2/2 mice, with
TAG comprising as much as 30% of its weight. The resulting
cardiac dysfunction causes death as early as 12 weeks of age
(23,24). Increased glucose use in the Atgl2/2 mice suggested
that the low rates of lipolysis in adipose stores were insuffi-
cient to supply fatty acids for normal b-oxidation (23), or
that the rate of fatty acid oxidation is low (25). It is now ap-
parent that the murine cardiomyopathy is caused, in part, by
a lack of peroxisome proliferator-activated receptor-a
Figure 3. Correction of the mutant cell phenotype by over expressing wild-type ATGL. (A) Upper images are from fibroblasts from patient 1A and a control
cultured at comparable passages in MEM plus Earle’s salts containing FBS (10% v/v). Fixed cells (paraformaldehyde, 4% w/v) were stained with ORO and
nuclei counterstained with DAPI (blue). Lower images are from the patient’s fibroblasts (passage 8) that were cultured in the same medium as above and tran-
siently transfected with either pEGFP or pATGL-EGFP. After 24 h, the cells were fixed and stained with ORO. Fluorescence of EGFP and ATGL-EGFP fusion
proteins is in green. Images are representative of four independent transfections. Scale bar: 10 mm. (B) ORO-stained LDs of fibroblasts from patient 1A trans-
fected with either pEGFP or pATGL-EGFP were analyzed for number, dimension (cross-section area) and pixels per cell. The values represent the means of 70–
90 cells. Experiments were run in duplicate.
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(PPARa) activation of b-oxidation target genes and that
PPARa agonists can partially correct the cardiomyopathy
(26).
Human ATGL is a 504 amino acid protein with a patatin
domain in its N-terminal region (residues 1–251) which con-
tains a catalytic dyad that includes the active site serine
(Ser47) within a canonical GXSXG site and the critical aspar-
tic acid residue (Asp166) (9). Within the C-terminal half of the
protein, a hydrophobic region (315–360) is required for
binding to LDs.
To date, 15 different mutations of the ATGL gene have been
reported in 18 patients. In the present manuscript, we have
clinically and genetically described an additional four patients
with three new mutations. In order to highlight the complex
effects that different ATGL gene variations may have on the
lipase activity, we have performed a functional characteriza-
tion of the novel, as well as the previously reported ATGL mis-
sense mutations.
The p.Arg221Pro and p.Asn172Lys mutations identified in
our NLSD-M patients are located in a highly conserved
Figure 4. Transient transfection of ATGL mutant proteins in HeLa cells. (A) HeLa cells, loaded for 18 h with OA (400 mM) complexed to BSA (6:1 molar ratio),
were transiently transfected with one of the following plasmids: pEGFP, pATGL-EGFP, pATGL(Ser47Ala)-EGFP, pATGL(Asp166Gly)-pEGFP,
pATGL(Asn172Lys)-EGFP, pATGL(Pro195Leu)-EGFP, pATGL(Arg221Pro)-EGFP and pATGL(Gly483Arg)-EGFP. After 24 h, the cells were fixed and
stained with ORO. Fluorescence of EGFP and ATGL-EGFP fusion proteins is in green. Scale bar: 10 mm. (B and C) ORO-stained LDs of Hela cells non-
transfected and transfected with pEGFP (V), pATGL-EGFP (WT), pATGL(Ser47Ala)-EGFP (M0), pATGL(Asp166Gly)-pEGFP (M1),
pATGL(Asn172Lys)-EGFP (M2), pATGL(Pro195Leu)-EGFP (M3), pATGL(Arg221Pro)-EGFP (M4) and pATGL(Gly483Arg)-EGFP (M5) plasmids. The cells
were analyzed for number (b) and dimension (c) (cross-section area) of LDs per cell. The values represent the means of 80–95 cells for each transfected
mutant. Experiments were run in triplicate.
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region within the a/b/a sandwich structure, and both include
and extend from the patatin domain. Our data suggest that
these amino acid changes might perturb the conformation of
the catalytic site and affect lipase activity, whereas binding
to the LD would remain unaffected.
The p.Arg221Pro mutation was homozygous in patients 1A
and 1B, whereas the p.Asn172Lys was heterozygous in
patients 2A and 2B who also had the p.Trp8X mutation.
Since the c.24G.C ATGL allele (p.Trp8X) can be considered
to be a null allele, only the contribution of p.Asn172Lys
ATGL protein may be critically evaluated for the clinical
phenotype. In the literature, a very young patient carrying a
p.Asp166Gly mutation in homozygous status was reported
(14). The p.Asp166Gly mutation disrupts the catalytic
dyad, comprised of Ser47 and Asp166, and abolishes lipase
activity, despite binding to LDs. The patient carrying the
p.Asp166Gly mutation presented with a severe cardiomyop-
athy and is currently awaiting a cardiac transplant, confirming
the highly deleterious effect of a total deficiency in
ATGL activity. Our functional studies using recombinant
ATGL(Asp166Gly) protein confirm that the lipase activity is
completely abrogated, similar to the ATGL(Ser47Ala)
protein (Fig. 4B, M0 and M1). In the ATGL gene, only one
other missense mutation, c.584C.T, has been reported; this
mutation leads to an amino acid change within the a/b-fold
at position 195 (p.Pro195Leu). Although this change does
not directly affect the catalytic site, the p.Pro195Leu protein
has defective lipase activity, but interacts with CGI-58 and,
like the ATGL from our patients, is located on LDs (3). The
c.584C.T (p.Pro195Leu) mutation was heterozygous in the
reported NLSD-M patient (8), with a second allele harboring
a c.808delC mutation (p.Leu319X). This patient presented
with a mild phenotype (mild myopathy and hepatomegaly);
the presence of cardiomyopathy was not ascertained (see Sup-
plementary Material). Because the second allele retains
enzyme activity (p.Leu319X), it may be able to partially com-
pensate for the catalytically inactive p.Pro195Leu. Recently,
the c.584C.T (p.Pro195Leu) mutation was identified in
homozygous status in a patient with distal muscle weakness,
elevated plasma CK and a cardiomyopathy (27). In accordance
with the clinical phenotype, our data on mutant transfection
show that p.Pro195Leu ATGL protein activity is highly
impaired and resembles that of p.Ser47Ala (Fig. 4, M3). In
the same patient, the p.Gly483Arg mutation was also identi-
fied, but this variation is most probably a benign polymorph-
ism (Fig. 4, M5).
The patients whose mutations are reported here are limited
physically by their skeletal myopathy but cardiac involvement
appears to be relatively mild. The functional data obtained
from transient transfection clearly show that the
p.Arg221Pro and p.Asn172Lys ATGL proteins localize cor-
rectly to the LD surface (Fig. 4A). Moreover, the
p.Arg221Pro protein shows less activity in comparison with
p.Asn172Lys ATGL (Fig 4B, M2 and M4). Although they
are likely to contribute only minimal lipase activity in vivo,
it appears that the small amount of residual enzymatic function
has protected patients 2A and 2B, who are now 58 and
66 years old, from the early onset of heart failure and arrhyth-
mias. The latter observation appears particularly relevant also
in consideration that they were older than NLSD-M patients
reported so far (27), thus suggesting a slow progression of car-
diomyopathy in these patients.
Compared with control fibroblasts, the fibroblasts from
NLSD-M patients 1A and 1B contain higher amounts of the
saturated and monounsaturated long-chain fatty acids, palmit-
ic, stearic and OA. In contrast, the content of very-long-chain
polyunsaturated fatty acids is lower in NLSD-M fibroblasts
than in controls. It is not known whether these differences in
fatty acid species are present in tissues of patients with
NLSD-M or whether they contribute to the clinical phenotype.
The prognosis of patients 1A and 1B remains uncertain
because (i) the p.Arg221Pro ATGL protein retains only a
small amount of catalytic activity (Figs 2 and 4, M4), and
(ii) among the 12 NLSD-M patients with cardiomyopathy
described to date, 11 cases were clinically silent until the
patients were 30–40 years old. As previously reported for
another young patient (15), our Lebanese patients pose the
crucial clinical dilemma of prognosis. The clinical course of
these patients will be important to follow in order to determine
whether their minimal ATGL lipase activity is sufficient to
prevent heart failure. NLSD-I patients, also known as Cha-
narin Dorfman patients, do not develop cardiomyopathy. In
these patients, ATGL is normally expressed but its enzymatic
activity is low, since the coactivator, CGI-58, does not func-
tion or is absent. Our data suggest that low, but correctly loca-
lized ATGL lipase activity in human cardiomyocytes might
preserve NLSD-M patients from severe cardiac dysfunction.
In patients similar to ours, it could be helpful to increase
ATGL mRNA expression or to reduce the amount of the
ATGL inhibitor protein G0S2 in order to improve ATGL
protein synthesis. Although dexamethasone can up-regulate
ATGL mRNA expression in vitro, it has little effect on cells
from NLSD-M patients (27). Beta-adrenergic agonists,
however, may inhibit G0S2 protein expression, thereby im-
proving ATGL enzymatic activity (28). Overexpression of
ATGL improved the disease phenotype in fibroblasts from
our patients; thus, enzyme replacement therapy may be thera-
peutic. Supplying exogenous human recombinant enzyme
improves the clinical outcome of several genetic diseases, in-
cluding Fabry disease and glycogen storage disease 2 (29,30).
Recently, it was demonstrated that the low abundance of
mRNA for PPARa target genes and the cardiac dysfunction
of Atgl2/2 mice can be corrected by the synthetic PPARa
agonist Wy14 643 which increases energy supply to the
heart through increased rates of FA b-oxidation (26). In
vitro experimental studies on human cardiomyocytes are
needed in order to verify the potential therapeutic effects of
PPARa and/or beta-adrenergic agonists and to develop thera-
peutic protocols for NLSD-M patients.
Although all reported NLSD-M patients suffer from muscle
weakness and skeletal muscle myopathy, the phenotypic se-
verity appears to be highly variable. Cardiomyopathy was
lethal in some patients or necessitated cardiac transplantation
in young patients, but older NLSD-M patients have been
described with less severe cardiac involvement (27). In the
present study, we provide biochemical evidence that might
help to explain the variable degrees of myopathy and cardio-
myopathy in NLSD-M. Additional larger clinical studies are
warranted to definitively elucidate genotype–phenotype corre-
lations of NLSD-M mutations. Such studies may improve
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disease prognosis and aid in developing personalized
approaches in treating patients with ATGL deficiency.
MATERIALS AND METHODS
Subjects
Human skin fibroblasts from a previously described patient
(18), two previously unreported patients and a control
subject were obtained from skin biopsies and cultured in
Earle’s minimum essential media (MEM) with 10% fetal
bovine serum (FBS), 100 IU/ml penicillin and 100 mg/ml
streptomycin at 378C in a 5% CO2 incubator. Informed
consent was obtained from the study participants.
Amplification and sequencing of ATGL genomic DNA
fragments
Genomic DNA was extracted using a Puregene DNA isolation
kit (Gentra Systems, Minneapolis), according to the manufac-
turer’s instructions. To amplify the sequences of ATGL exons
(GeneBank NM02376), we used eight primer pairs. PCR was
performed with 200 ng of genomic DNA. Primer sequences
and PCR amplification conditions for the analysis of ATGL
coding regions were previously reported (8). All PCR products
were purified (NucleoSpin Extract II; M-Medical) and
sequenced on 3730 DNA analyzers by the BigDyew Termin-
ator V1.1 Cycle sequencing kit (Applied Biosystems, Foster
City, CA, USA).
RT-PCR analysis of ATGL mRNA expression in fibroblasts
Total RNA (1 mg) isolated from fibroblasts with TRIzol (Invi-
trogen, Carslbad, CA, USA) was converted to cDNA by
RT-PCR using random hexamers (0.5 mg), 400 units of
MMLV-RT, 1.6 mM total dNTPs, 20 units of Rnasin and
0.4 mM dithiothreitol, in a 50 ml reaction solution containing
10× RT Buffer. Forty nanograms of cDNA were used to
perform PCR amplification using ATGL-3F (5′-TCTAAAGA
GGCCCGGAAGCG-3′) and ATGL-6R (5′-TTCAGGAGGCG
TTCCGCTG-3′) primers designed to produce a 551 bp frag-
ment of the ATGL transcript (Accession No. AY894804.1
GI:58759050). PCR conditions for ATGL3F/6R primers
were as follows: denaturation at 958C for 3 min, annealing
at 578C for 30 s and extension at 728C for 30 s for the first
round, denaturation at 948C for 30 s, annealing at 578C for
30 s and extension at 728C for 30 s for 28 cycles; denaturation
at 948C for 30 s, annealing at 578C for 30 s and terminal ex-
tension at 728C for 3 min for the last cycle. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase, gene expression
was used as the internal control (31). The PCR products
were electrophoresed on a 2% agarose gel containing ethidium
bromide.
Western blot analysis of ATGL protein expression in
fibroblasts
Cell extracts were prepared from confluent cultures grown in
serum-containing medium. After extensive washing with
cold PBS, cells were recovered by scraping with a rubber
policeman in 1 ml of 0.05% (wt/vol) sodium dodecyl sulfate
(SDS). The total protein concentration of cell extracts was
quantified by a Coomassie (Bradford) protein assay kit
(PIERCE). Laemmli’s polyacrylamide gel electrophoresis, in
the presence of SDS and under reducing conditions, was
carried out using a 12% vertical slab gel. Proteins (25 mg/
well) were loaded, then immunoblotted using a mouse poly-
clonal antibody (dil. 1:5000) raised against full-length recom-
binant ATGL protein (ABNOVA, Taiwan corporation) and a
mouse monoclonal antibody (dil: 1:7000) to GAPDH
(Ambion, Austin, TX, USA). Specifically bound immunoglo-
bulins were detected using the SuperSignal West Pico
Complete Mouse Detection Kit (PIERCE) containing
ImmunoPure Peroxidase Conjugated Goat anti-Mouse IgG
(dil 1:20.000).
Cloning the ATGL cDNA and generation of site-directed
mutagenesis plasmids
ATGL cDNA was amplified by PCR using DNA clone ID
4875483 (Open Biosystem) as template. The PCR product was
cloned into pEGFP-N1 from Clonetech to produce pEGFP-
N1-ATGL, expressing ATGL with GFP at the C-terminus.
Point mutations were performed using the QuikChange XL site-
directed mutagenesis kit (Stratagene). Mutations in ATGL
cDNA were introduced using the following primers:
Ser47Ala: forward 5′-CACATCTACGGCGCCGCGGCCGG
GGCGCTCACGG-3′ and reverse 5′-CCGTGAGCGCCCCG
GCCGCGGCGCCGTAGATGTG-3′; Asp166Gly forward 5′-T




ATGCC-3′; Pro195Leu forward 5′-GAGTGACATCTGTCT




TGCGCAGG-3′ Gly483Arg forward 5′-ACCAGCTGGCCC
GGCCTGCCC-3′ and reverse 5′-GGGCAGGCCGGGCCAG
CTGGT-3′. All constructs were verified by DNA sequencing.
Expression of recombinant ATGL plasmids in HeLa cells
HeLa cells were cultured on glass coverslips in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS and
allowed to adhere overnight. To increase TAG synthesis and
storage, 400 mM oleate complexed to BSA (6:1 molar ratio)
was added to the medium and incubated overnight. The cells
were then transiently transfected with recombinant pEGFP
ATGL plasmids [pEGFP, pATGL-EGFP, pATGL(Ser47Ala)-
EGFP, pATGL(Asp166Gly)-EGFP, pATGL(Asn172Lys)-
EGFP, pATGL(Pro195Leu)-EGFP, pATGL(Arg221Pro)-EGFP
and pATGL(Gly483Arg)-EGFP] using the siPORT XP-1 trans-
fection reagent, according to the manufacturer’s protocol
(Ambion). After 24 h, the cells were fixed and stained with
ORO, and LDs from immunofluorescent images were quanti-
fied.
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TLC analysis
Total cellular lipid extracts (8:4:3 v/v chloroform–methanol–
water solution) were dried in a centrifugal vacuum concentra-
tor (SPD111V; Thermo Electron Corp., Madison, WI, USA) at
308C then re-dissolved in 20 ml of chloroform/methanol
(2:1 v/v). Aliquots were applied onto silica gel thin-layer chro-
matography (TLC) plates (60 G, 100 × 200 × 0.25 mm;
Merck AG, Darmstadt, Germany) and separated in a solvent
system of hexane/diethyl ether/formic acid (80:20:2; v/v).
The developed plates were heated at 1108C for 30 min, then
cooled at RT, sprayed with 50% (v/v) sulfuric acid solution
in ethanol and redried at 1708C for 20 min. Qualitative and
quantitative analyses of individual lipid classes were made
through comparison with standards (cholesterol oleate, trio-
lein, 1,3-dioleoyl-sn-glycerol, 1,2-dioleoyl-sn-glycerol, sn-1-
and 2-monooleoyl glycerol and 3-sn-phosphatidic acid
sodium salt; Sigma-Aldrich).
Fatty acid composition of TAG
Purified TAG for gas–liquid chromatography (GLC) analysis
was obtained from the TLC plates. TAG bands were detected
by exposing the developed TLC plates to iodine vapor. After
iodine sublimation, the TAG spots were scraped from the
silica gel plates, and TAG was extracted with methanol.
After evaporating the solvent, the TAG was transmethylated
at 508C for 1 h with BF3/methanol (40% w/v). After evapor-
ation, fatty acid methyl esters were re-dissolved in hexane
and analyzed with a Hewlett-Packard model 5700A (Round
Rock, TX, USA) gas chromatograph equipped with a
SP-1000 column (30 m × 0.25 mm ID; Supelco Inc., Bella-
fonte, Pennsylvania , USA) and a flame ionization detector.
Lipid standards were obtained from Sulpelco Inc. FFA
C23:0 was used as the internal standard for TAG quantifica-
tion.
Oleic acid pulse-chase experiments on disease and control
fibroblasts
Oleic acid (O-1630, Sigma) was dissolved in a 2.1 mM solu-
tion of FFA-free BSA, previously prepared in 0.1 M Tris (pH
8), to a final concentration of 12.5 mM. After the fatty acid
was completely dissolved, the solution was heated to 378C,
then cooled, filtered on 0.20 mM Minisart and stored in aliquots
at 48C.
Metabolic pulse experiment with 400 mM oleic acid
Fibroblasts (200 000 per dish) were seeded on coverslips in a
serum-free Earle’s MEM culture medium and allowed to
adhere for 7 h. Then the cell culture medium was supplemen-
ted with the 12.5 mM oleate/BSA solution at a final concentra-
tion of 400 mM (pulse medium). After an overnight incubation,
the medium was removed, and the cells were washed
with Dulbecco’s phosphate-buffered saline (D-PBS) and
stained with Nile Red (NR) dye (NR, 9-diethylamino-5H-
benzo[alpha]phenoxazine-5-one; Sigma-Aldrich).
Metabolic pulse-chase experiment with 200 mM oleic acid
For the oleic acid (OA) pulse-chase experiment, control and
patient fibroblasts were seeded on glass coverslips and
grown in a serum-free Earle’s MEM culture medium to 90%
confluence, then incubated for 24 h in a culture medium con-
taining OA/BSA (200 mM). The day after, in some (1/4) of the
dishes, the medium containing OA/BSA was removed, the
cells were washed twice with D-PBS, fixed on the coverslips
with 4% paraformaldehyde, and labeled with NR dye. Fibro-
blasts in the remaining dishes were washed twice with
D-PBS, and then incubated for 48, 72 or 96 h in the serum-free
Earle’s MEM culture medium containing fatty acid-free BSA
(2% w/v) to enhance cellular lipolysis (chase). BSA was
present in the medium to capture OA released from cells. At
the end of each chase (48, 72 and 96 h), the medium was
removed, and the cells were washed twice with D-PBS and
stained with NR. Quantitative analysis of fatty acid stores
used ‘WCIF ImageJ 1.35j’ software that allowed evaluation
of pixels per cell related to NR emission.
Metabolic pulse-chase experiment with 200 mM OA enriched
with [3H]OA
Confluent fibroblasts (1.5 × 105 cells/well) were incubated
with OA (200 mM) complexed to BSA and enriched with
[3H]OA (1.2 mCi/well). After 18 h, the cells were washed,
and the medium was replaced by MEM plus Earle’s salts con-
taining fatty acid-free BSA (3% w/v) and triacsin C (5 mM).
[3H]OA release into the medium was determined in aliquots
of the water phase by liquid scintillation counting.
Acylglycerol hydrolase activity of lipid droplets isolated
from fibroblasts
Isolation of the LD fraction was performed as described by
Fujimoto et al. (32). The acylglycerol hydrolase activity of
LDs isolated from control and patient fibroblasts was mea-
sured at three different pH values (6, 7.2 and 8) in 40 mM po-
tassium phosphate buffer containing fatty acid-free BSA (2%
w/v) and using [3H]trioleoylglycerol (40 000 cpm/nmol) as
the substrate. After an incubation of 30 min at 378C, the reac-
tion was terminated by extraction of the alkalinized mixture
with an organic phase. Free [3H]OA was determined in ali-
quots of the water phase by liquid scintillation counting.
Transient transfection of wild-type ATGL cDNA in disease
fibroblasts
Patient’s fibroblasts were cultured on glass coverslips until
80% of confluence and transiently transfected with either
pEGFP or ATGL-EGFP plasmid with the siPORT XP-1 trans-
fection reagent (Ambion). After 24 h, the cells were fixed and
stained with ORO, and LDs were quantified from immuno-
fluorescent images.
Immunofluorescence microscopy
NR staining solution was freshly prepared in DPBS (1:100 v/
v) from a saturated solution (1 mg/ml) in dimethyl sulfoxide.
The cells were fixed on a glass slide using 4%
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paraformaldehyde. After rinses with distilled water, slides
were incubated with NR solution for 20 min in the dark.
A 1.66× solution of ORO was prepared as reported by
Koopman et al. (33). The cells fixed on glass coverslips
were incubated with 2 ml of fresh 1X ORO solution for
30 min under darkened conditions.
After washing with 2 ml of distilled water, fibroblasts and
HeLa transfected cells labeled with lipophilic dyes (ORO
and NR) were mounted on glass microscope slides with Vec-
tashield mounting medium (Vector Laboratories, Burlingame,
CA, USA) and examined with a Leica MB5000B microscope
equipped with 20×, 40× and 100× Fluorart oil immersion
objectives. Excitation fluorescence filters used for ORO and
NR images were TX2-FITC (540–580 nm) and I3-TRITC
(450–490 nm), respectively. Fluorescence images were cap-
tured using a Leica DFC480 R2 digital camera and the
Leica Application Suite (LAS) software that allows one to
change a large number of measurement parameters. The
values chosen for the exposure time, saturation, gamma and
gain parameters were, respectively, 4 s, 1.2, 1.43, 1× for
ORO stained fibroblasts and 1 s, 1.1, 1.21, 1.1× for NR
stained fibroblasts. In HeLa transfected cells stained with
ORO, the values for the exposure time, saturation, gamma
and gain parameters were, respectively, 12 s, 1.20, 1.43, 5×.
Fluorescent images captured by immunofluorescent micros-
copy were analyzed using the public domain Java image pro-
cessing program ‘WCIF ImageJ 1.35j’ (developed by
W. Rasband, NIH, Bethesda, MD, USA). This software
allows us to isolate components having the same wavelength
and to evaluate and quantify several parameters like area,
numbers of selected units (LDs, in this case) and pixels per
cell; 15 inches2 was chosen as threshold value for LD area
in order to discard fluorescent emissions due to impurity.
Statistical analysis
The statistical analysis of quantitative data on LDs identified
from cells (fibroblasts and HeLa transfected cells) by image
analysis of immunofluorescence experiments as well as those
obtained from TLC, TLC–GLC, the pulse-chase experiments
and the acylglycerol hydrolase activity assay was made using
SPSS v.19 package (SPSS, Chicago, IL, USA). The values
were compared with Student’s unpaired t-test, x2-squared
test and linear regression analysis using Spearman’s software.
A P-value of ≤0.05 was considered to be statistically signifi-
cant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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